Drug intelligence / Profile preview

DWJ1511

Development stage: Phase 1
Lead developer: Daewoong Pharmaceutical

Overview

DWJ1511 is an investigational pharmaceutical drug under clinical evaluation for its pharmacokinetic and safety profile in humans. It is being compared to DWC202501 in a crossover, single-dose study design for assessment of drug exposure and safety outcomes. The mechanism of action, structure, therapeutic class, and specific indication for DWJ1511 are not disclosed in public sources at this time. Both drugs are being evaluated for their plasma concentration–time curve, suggesting a clinical trial focused on bioequivalence or comparative pharmacology[1].

Beyond the preview

Go deeper on DWJ1511.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWJ1511.

Explore the full profile